No retraction, correction or concern found when last checked on Nov 5, 2026.

Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera

Daming Zhou, Wanwisa Dejnirattisai, Piyada Supasa and 41 more (opens in a new tab)

Cell · 2021 · CC BY

doi:10.1016/j.cell.2021.02.037 (opens in a new tab)

Abstract

The race to produce vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) began when the first sequence was published, and this forms the basis for vaccines currently deployed globally. Independent lineages of SARS-CoV-2 have recently been reported: UK, B.1.1.7; South Africa, B.1.351; and Brazil, P.1. These variants have multiple changes in the immunodominant spike protein that facilitates viral cell entry via the angiotensin-converting enzyme-2 (ACE2) receptor. Mutations in the receptor recognition site on the spike are of great concern for their potential for immune escape. Here, we describe a structure-function analysis of B.1.351 using a large cohort of convalescent and vaccinee serum samples. The receptor-binding domain mutations provide tighter ACE2 binding and widespread escape from monoclonal antibody neutralization largely driven by E484K, although K417N and N501Y act together against some important antibody classes. In a number of cases, it would appear that convalescent and some vaccine serum offers limited protection against this variant.

References 37

1.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
2.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
3.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
4.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
5.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
6.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
7.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
8.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
9.
Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies · 2020
No notice
10.
A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2 · 2020
No notice
11.
Structural basis of a shared antibody response to SARS-CoV-2 · 2020
No notice
12.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
13.
Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding · 2020
No notice
14.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
15.
Tracking the COVID-19 pandemic in Australia using genomics · 2020
No notice
16.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
17.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
18.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
19.
Robust neutralizing antibodies to SARS-CoV-2 infection persist for months · 2020
No notice
20.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
21.
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK · 2021
Corrected
22.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
23.
Molecular determinants and mechanism for antibody cocktail preventing SARS-CoV-2 escape · 2021
Corrected
24.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
25.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
26.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
27.
The antigenic anatomy of SARS-CoV-2 receptor binding domain · 2021
No notice
28.
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials · 2021
Corrected
29.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
30.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
31.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
32.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
33.
SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma · 2021
No notice
34.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
35.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
36.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
37.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library

Cited by papers we hold 37

Structural and functional characterizations of infectivity and immune evasion of SARS-CoV-2 Omicron · 2022
Corrected
Dual spike and nucleocapsid mRNA vaccination confer protection against SARS-CoV-2 Omicron and Delta variants in preclinical models · 2022
No notice
Cooperative multivalent receptor binding promotes exposure of the SARS-CoV-2 fusion machinery core · 2022
Not checked
SARS-CoV-2 variants of concern surveillance including Omicron using RT-PCR–based genotyping offers comparable performance to whole genome sequencing · 2022
Not checked
Immunogenicity of ChAdOx1 nCoV-19 vaccine after a two-dose inactivated SARS-CoV-2 vaccination of dialysis patients and kidney transplant recipients · 2022
Not checked
Preclinical immunological evaluation of an intradermal heterologous vaccine against SARS-CoV-2 variants · 2022
Not checked
Neutralizing antibody responses elicited by SARS-CoV-2 mRNA vaccination wane over time and are boosted by breakthrough infection · 2022
No notice
SARS-COV-2 Variants: Differences and Potential of Immune Evasion · 2022
No notice
COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection · 2022
No notice
A Detailed Overview of Immune Escape, Antibody Escape, Partial Vaccine Escape of SARS-CoV-2 and Their Emerging Variants With Escape Mutations · 2022
No notice
COVID-19 vaccine development: milestones, lessons and prospects · 2022
No notice
Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis · 2022
No notice
The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans · 2022
No notice
SARS-CoV-2 Variants, Vaccines, and Host Immunity · 2022
No notice
T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study · 2022
No notice
SARS-CoV-2 prolonged infection during advanced HIV disease evolves extensive immune escape · 2022
No notice
Divergent SARS-CoV-2 Omicron–reactive T and B cell responses in COVID-19 vaccine recipients · 2022
No notice
Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals · 2021
No notice
Meta-Analysis and Structural Dynamics of the Emergence of Genetic Variants of SARS-CoV-2 · 2021
Not checked
Standardised neutralising antibody assays are needed for evaluating COVID-19 vaccines · 2021
Not checked

and 17 more

Questions about this paper

We email you if it is retracted, withdrawn, corrected or flagged.

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.